Anti-HER2×CCR4 Bispecific Antibody Enhances Antitumor Immunity in Advanced HER2-Positive Tumors by Chemotaxis Blockade and Depletion of Tumor-Associated Tregs, Without Inducing Systemic Toxicity
雜志期刊:Journal for Immuno Therapy of Cancer
影響因子:10.6
客戶單位:南開大學藥學院
助力服務:PBMC, CD8+T細胞,CD4+T細胞,CD34+ HSC細胞分離服務